Alcobra announces positive results from pre-clinical studies of of its autism treatment MG01C1

Alcobra (ADHD +5.6%) gains after announcing positive findings from a pre-clinical study of MG01CI in a mouse model of Fragile X Syndrome.

The study showed "significant" improvement in both cognitive and social functioning following treatment.

Fragile X syndrome is the most common single-gene cause of autism and inherited cause of intellectual disability among boys.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs